(Total Views: 576)
Posted On: 05/24/2025 11:33:09 PM
Post# of 153902
The prolongation of TMZ treatment from 6 to 12 cycles extended neither progression-free nor overall survival [44].
April 2021 Journal GBM Dr. Pestell included:
2.3. Glioblastoma Therapy
The standard-of-care therapeutic modalities for GBM (including maximally safe surgical resection, irradiation (IR), chemotherapy with alkylating agent temozolomide (TMZ), and frequency electrotherapy of tumor treating fields (TTF) [32] has increased median patient survival from approximately16 months to 20 months after diagnosis.
The high levels of GBM cell outgrowth throughout the brain make surgical resection mostly incomplete and prevent IR from being focused. Moreover, GSC plasticity, as described above, promotes therapy resistance to a much greater extent than the blood–brain barrier that is mostly compromised in glioblastoma tumors.
Thus, unlike many other cancer types, in which targeted therapies have improved survival substantially, there have not been similar advances in GBM treatment [41].
Resistance of GBM is a serious problem, preventing effective treatment. The EANO and International Brain Tumor Study Group demonstrated that dose intensification fails to improve patient survival [17,42].
The combination of TMZ (standard maintenance chemotherapeutic in GBM) and IR (CATNON Trial) prolonged survival only in patients with IDH-mutant astrocytoma WHO grade 3 and not in those with GBM [43].
The prolongation of TMZ treatment from 6 to 12 cycles extended neither progression-free nor overall survival [44].
https://www.mdpi.com/1422-0067/22/9/4464
____
Cytodyn March update:
A preclinical study at the Albert Einstein College of Medicine sequencing temozolomide and leronlimab is now underway.
CytoDyn is also in discussions with several KOLs in neuro-oncology about the possibility of initiating a pilot study in patients with GBM, also based on currently available data.
___
Our TMZ combo & GMB trial is a search for a new SOC is how i read it, because of #'s 43 & 44 from above:
" The combination of TMZ (standard maintenance chemotherapeutic in GBM) and IR (CATNON Trial) prolonged survival only in patients with IDH-mutant astrocytoma WHO grade 3 and not in those with GBM [43]. "
___
Our GMB now reminds of mTNBC --- ICI's not treating 85% of patients.
With GBM being a cold tumor.
Temozolomide dose not treat all GBM.
Maybe this time we delivered a combo LL / ICI
& unlike current trials failing with GBM/ICI's.....we will have a trio of break-throughs:
mTNBC
CRC
GMB
April 2021 Journal GBM Dr. Pestell included:
2.3. Glioblastoma Therapy
The standard-of-care therapeutic modalities for GBM (including maximally safe surgical resection, irradiation (IR), chemotherapy with alkylating agent temozolomide (TMZ), and frequency electrotherapy of tumor treating fields (TTF) [32] has increased median patient survival from approximately16 months to 20 months after diagnosis.
The high levels of GBM cell outgrowth throughout the brain make surgical resection mostly incomplete and prevent IR from being focused. Moreover, GSC plasticity, as described above, promotes therapy resistance to a much greater extent than the blood–brain barrier that is mostly compromised in glioblastoma tumors.
Thus, unlike many other cancer types, in which targeted therapies have improved survival substantially, there have not been similar advances in GBM treatment [41].
Resistance of GBM is a serious problem, preventing effective treatment. The EANO and International Brain Tumor Study Group demonstrated that dose intensification fails to improve patient survival [17,42].
The combination of TMZ (standard maintenance chemotherapeutic in GBM) and IR (CATNON Trial) prolonged survival only in patients with IDH-mutant astrocytoma WHO grade 3 and not in those with GBM [43].
The prolongation of TMZ treatment from 6 to 12 cycles extended neither progression-free nor overall survival [44].
https://www.mdpi.com/1422-0067/22/9/4464
____
Cytodyn March update:
A preclinical study at the Albert Einstein College of Medicine sequencing temozolomide and leronlimab is now underway.
CytoDyn is also in discussions with several KOLs in neuro-oncology about the possibility of initiating a pilot study in patients with GBM, also based on currently available data.
___
Our TMZ combo & GMB trial is a search for a new SOC is how i read it, because of #'s 43 & 44 from above:
" The combination of TMZ (standard maintenance chemotherapeutic in GBM) and IR (CATNON Trial) prolonged survival only in patients with IDH-mutant astrocytoma WHO grade 3 and not in those with GBM [43]. "
___
Our GMB now reminds of mTNBC --- ICI's not treating 85% of patients.
With GBM being a cold tumor.
Temozolomide dose not treat all GBM.
Maybe this time we delivered a combo LL / ICI
& unlike current trials failing with GBM/ICI's.....we will have a trio of break-throughs:
mTNBC
CRC
GMB
(7)
(0)
